An epidemiological evaluation of salivary gland cancer in the Netherlands (1989–2010)

Ridder, Mischa de; Balm, Alfons J. M.; Smeele, Ludi E.; Wouters, Michel W. J. M.; Dijk, Boukje A. C. van

doi:10.1016/j.canep.2014.10.007

Cited by 39 publications

(49 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There is general agreement in the literature that the parotid gland is the most frequent anatomical site for MSGTs (10,24,30). In our series, 82.6% of tumors were located in major salivary glands: 65.3% in parotid glands and 17.4% in submaxillary glands.…”

Section: Discussionsupporting

confidence: 76%

“…In contrast, we noted an annual incidence of 0.91 cases per 100,000 inhabitants during the period between January 2004 and December 2012. Table 4 (7,10,(24)(25)(26)(27)(28)(29) shows the reported incidences of MSGTs, according to geographical setting. The figures vary but are low in all cases, ranging from 0.2 to 1.3 cases per 100,000 inhabitants per year.…”

Section: Discussionmentioning

confidence: 99%

“…A retrospective study of 1,392 patients with MSGTs found that the most frequent tumor type was mucoepidermoid carcinoma (8), as did another study, which enrolled 1,268 patients (9). However, a study of 2,737 patients found that the most common histological type was adenoid cystic carcinoma (10). This illustrates the controversy and variability regarding the different histological types described in the literature.…”

Section: Introductionmentioning

confidence: 95%

See 2 more Smart Citations

Incidence and survival rates for malignant salivary gland tumors

2016

View full text Add to dashboard Cite

The aims of this study were to determine the incidence of malignant salivary gland tumors (MSGTs) in a specific in Spanish Mediterranean population, evaluate oncological outcomes, and identify prognostic factors for survival. Overall survival and disease-free survival rates were calculated for 23 patients with MSGTs who were treated in our department during 2004-2012. In the recruitment population of the reference hospital, annual incidence per 100,000 inhabitants was estimated, with corresponding 95% confidence intervals (CIs). The mean annual incidence of MSGTs was 0.91 new cases per 100,000 inhabitants (95% CI, 0.14-2.83). The most common histological type was squamous cell carcinoma (34.8%). Overall survival ranged from 2 to 120 months (mean 70.5 months). The 5-year overall survival rate was 52.5%, and the 5-year disease-free survival rate was 50%. The mean disease-free interval was 73.9 months (95% CI 47.1-100.

show abstract

Section: Discussionsupporting

confidence: 76%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 95%

See 1 more Smart Citation

Incidence and survival rates for malignant salivary gland tumors

2016

View full text Add to dashboard Cite

show abstract

“…Boukheris et al (29) compared the incidence of large salivary gland neoplasms in the American population according to the sex and age of 6391 patients. Among men with the most common neoplasms, a more frequently occurring cancer was squamous cell carcinoma (20% with men and 8% with women).…”

Section: Histopathological Types and Anatomical Locationmentioning

confidence: 99%

“…The worst prognosis was for adenocarcinoma (5-OS 50%) [11]. Similarly, in the Dutch population the best prognosis was for lobular cancer (5-year relative survival was 97% and the worst was for adenocarcinoma (54%) and squamous cell carcinoma (46%)) [29].…”

Section: Histopathological Types and Anatomical Locationmentioning

confidence: 99%

Salivary gland cancer — epidemiology

Kordzińska-Cisek¹,

Grzybowska‐Szatkowska²

2018

Nowotwory. Journal of Oncology

View full text Add to dashboard Cite

Salivary gland tumors represent 3-11% of all head and neck cancers and 0.2% of all neoplasms. Among Poles, malignancies involving the large salivary glands constituted 0.3% of all malignancies in Poland and 9.7% of head and neck neoplasms. In 2014, the morbidity rate was higher among women, but over the past 15 years there has been a slight prevalence among men. As for benign neoplasms in Poland, the most commonly seen are pleomorphic adenoma and Warthin's tumor. Cystic glandular cancer, mucoid epidermal carcinoma and adenocarcinoma are among the most frequent malignancies. Less common are lymphoma and squamous cell carcinoma. Salivary gland neoplasms are usually located in the parotid gland, then in the sub-mandibular gland. The best prognosis is for women whose cancers are located in the parotid gland and those with lobular carcinoma. Figures have been on the rise lately, however. Deaths have been on a stable level.

show abstract

Risk of breast cancer in women after a salivary gland carcinoma or pleomorphic adenoma in the Netherlands

Valstar

Schaapveld

Broek³

et al. 2020

Cancer Medicine

Self Cite

View full text Add to dashboard Cite

Salivary and mammary gland tumors show morphological similarities and share various characteristics, including frequent overexpression of hormone receptors and female preponderance. Although this may suggest a common etiology, it remains unclear whether patients with a salivary gland tumor carry an increased risk of breast cancer (BC). Our purpose was to determine the risk of BC in women diagnosed with salivary gland carcinoma (SGC) or pleomorphic adenoma (SGPA). BC incidence (invasive and in situ) was assessed in two nationwide cohorts: one comprising 1567 women diagnosed with SGC and one with 2083 women with SGPA. BC incidence was compared with general population rates using standardized incidence ratio (SIR). BC risk was assessed according to age at SGC/SGPA diagnosis, follow‐up time and (for SGC patients) histological subtype. The mean follow‐up was 7.0 years after SGC and 9.9 after SGPA diagnosis. During follow‐up, 52 patients with SGC and 74 patients with SGPA developed BC. The median time to BC was 6 years after SGC and 7 after SGPA. The cumulative risk at 10 years of follow‐up was 3.1% after SGC and 3.5% after SGPA (95% Confidence Interval (95%CI) 2.1%–4.7% and 2.6%–4.6%, respectively). BC incidence was 1.59 times (95%CI 1.19–2.09) higher in the SGC‐cohort than expected based on incidence rates in the general population. SGPA‐patients showed a 1.48 times (95%CI 1.16–1.86) higher incidence. Women with SGC or SGPA have a slightly increased risk of BC. The magnitude of risk justifies raising awareness, but is no reason for BC screening.

show abstract

An epidemiological evaluation of salivary gland cancer in the Netherlands (1989–2010)

Cited by 39 publications

References 40 publications

Incidence and survival rates for malignant salivary gland tumors

Incidence and survival rates for malignant salivary gland tumors

Salivary gland cancer — epidemiology

Risk of breast cancer in women after a salivary gland carcinoma or pleomorphic adenoma in the Netherlands

Contact Info

Product

Resources

About